Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:BNTC NASDAQ:IOVA NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$4.77-1.8%$5.13$4.57▼$8.69$1.81B0.422.77 million shs1.93 million shsBNTCBenitec Biopharma$12.98-0.1%$11.93$9.85▼$16.76$446.26M0.25151,500 shs65,265 shsIOVAIovance Biotherapeutics$3.93-2.7%$3.99$1.70▼$5.63$1.80B0.712.82 million shs13.33 million shsRXRXRecursion Pharmaceuticals$3.34+1.2%$3.34$2.77▼$7.18$1.75B121.68 million shs25.62 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-1.85%-3.05%-5.74%-17.20%-24.78%BNTCBenitec Biopharma-0.08%-3.42%+16.10%-4.56%-2.04%IOVAIovance Biotherapeutics-2.72%-9.66%-3.68%+2.88%+95.52%RXRXRecursion Pharmaceuticals+1.21%-13.02%+6.03%-10.93%-36.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$4.77-1.8%$5.13$4.57▼$8.69$1.81B0.422.77 million shs1.93 million shsBNTCBenitec Biopharma$12.98-0.1%$11.93$9.85▼$16.76$446.26M0.25151,500 shs65,265 shsIOVAIovance Biotherapeutics$3.93-2.7%$3.99$1.70▼$5.63$1.80B0.712.82 million shs13.33 million shsRXRXRecursion Pharmaceuticals$3.34+1.2%$3.34$2.77▼$7.18$1.75B121.68 million shs25.62 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-1.85%-3.05%-5.74%-17.20%-24.78%BNTCBenitec Biopharma-0.08%-3.42%+16.10%-4.56%-2.04%IOVAIovance Biotherapeutics-2.72%-9.66%-3.68%+2.88%+95.52%RXRXRecursion Pharmaceuticals+1.21%-13.02%+6.03%-10.93%-36.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.80Reduce$8.0067.89% UpsideBNTCBenitec Biopharma 2.56Moderate Buy$27.00108.01% UpsideIOVAIovance Biotherapeutics 2.30Hold$8.43114.47% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10142.51% UpsideCurrent Analyst Ratings BreakdownLatest BNTC, BHC, RXRX, and IOVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026IOVAIovance Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/10/2026BNTCBenitec Biopharma GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/14/2026RXRXRecursion Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $5.505/12/2026BNTCBenitec Biopharma EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$25.005/7/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.005/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/4/2026BHCBausch Health Cos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.004/27/2026BHCBausch Health Cos Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$10.00 ➝ $9.004/21/2026RXRXRecursion Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026BNTCBenitec Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$10.27B0.17$7.11 per share0.67$1.02 per share4.67BNTCBenitec BiopharmaN/AN/AN/AN/A$3.71 per shareN/AIOVAIovance Biotherapeutics$285.61M6.14N/AN/A$1.76 per share2.23RXRXRecursion Pharmaceuticals$74.68M23.70N/AN/A$2.14 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos$157M-$3.24N/A1.31N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)BNTCBenitec Biopharma-$37.92M-$1.14N/AN/AN/AN/A-34.82%-34.11%9/30/2026 (Estimated)IOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%8/6/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)Latest BNTC, BHC, RXRX, and IOVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026IOVAIovance Biotherapeutics-$0.17N/AN/AN/A$87.67 millionN/A8/4/2026Q2 2026RXRXRecursion Pharmaceuticals-$0.25N/AN/AN/A$10.97 millionN/A7/29/2026Q2 2026BHCBausch Health Cos$0.96N/AN/AN/A$2.56 billionN/A5/14/2026Q3 2026BNTCBenitec Biopharma-$0.27-$0.24+$0.03-$0.24$4.55 millionN/A5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos54.681.320.97BNTCBenitec BiopharmaN/A56.8256.82IOVAIovance BiotherapeuticsN/A3.603.15RXRXRecursion Pharmaceuticals0.015.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%BNTCBenitec Biopharma52.19%IOVAIovance Biotherapeutics77.03%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos20.67%BNTCBenitec Biopharma4.80%IOVAIovance Biotherapeutics7.80%RXRXRecursion Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,300374.03 million296.72 millionOptionableBNTCBenitec Biopharma2034.35 million32.71 millionNo DataIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million494.67 millionOptionableBNTC, BHC, RXRX, and IOVA HeadlinesRecent News About These CompaniesSumitomo Mitsui Trust Group Inc. Cuts Stock Position in Recursion Pharmaceuticals, Inc. $RXRX2 hours ago | marketbeat.comWhy Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market TodayJuly 14 at 11:51 PM | finance.yahoo.comWhy Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market TodayJuly 14 at 6:51 PM | zacks.comCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?July 14 at 8:13 AM | fool.comInsider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $158,400.00 in StockJuly 12 at 11:08 AM | americanbankingnews.com2 Beaten-Down Stocks That Still Aren't Worth BuyingJuly 11, 2026 | fool.comHsbc Holdings PLC Grows Position in Recursion Pharmaceuticals, Inc. $RXRXJuly 11, 2026 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 7.8% on Insider SellingJuly 10, 2026 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of "Hold" by BrokeragesJuly 10, 2026 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 40,000 SharesJuly 9, 2026 | marketbeat.comIs Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?July 9, 2026 | finance.yahoo.comHere's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketJuly 8, 2026 | finance.yahoo.comHere's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketJuly 8, 2026 | zacks.com3 Cancer Stocks to Watch as Oncology Innovation AcceleratesJuly 8, 2026 | zacks.com5 Best Penny Stocks to Invest In According to BillionairesJuly 7, 2026 | insidermonkey.comRecursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug HopesJuly 5, 2026 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed?July 5, 2026 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from BrokeragesJuly 5, 2026 | marketbeat.comDyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?July 4, 2026 | fool.comModerna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?July 3, 2026 | fool.comInvestors Purchase Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)July 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNTC, BHC, RXRX, and IOVA Company DescriptionsBausch Health Cos NYSE:BHC$4.76 -0.09 (-1.75%) Closing price 07/14/2026 03:59 PM EasternExtended Trading$4.80 +0.04 (+0.76%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Benitec Biopharma NASDAQ:BNTC$12.98 -0.01 (-0.08%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$12.90 -0.08 (-0.58%) As of 07/14/2026 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Iovance Biotherapeutics NASDAQ:IOVA$3.93 -0.11 (-2.72%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$3.94 +0.01 (+0.38%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Recursion Pharmaceuticals NASDAQ:RXRX$3.34 +0.04 (+1.21%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$3.38 +0.04 (+1.05%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
